Biogen Pays $1.25bn For Peace Of Mind Over Tecfidera, But Legal Wrangling Continues

Biogen's new CEO Michel Vounatsos has begun his tenure by taking out a $1.25bn "insurance policy" on MS drug Tecfidera by licensing Forward Pharma's patent portfolio, but the cost of the deal could spiral if the Danish firm wins a series of ongoing patent disputes with Biogen concerning Tecfidera and Forward Pharma's MS drug candidate FP187.